Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.51 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.51 |
| ▸ | CDC25B | P30305 | 8/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560625 | 0.88 | SSTR1 (0.53) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL20019530 | 0.86 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6890979 | 0.86 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7605821 | 0.84 | PTPN1 (0.58) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6562081 | 0.84 | PTPN1 (0.58) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL20019541 | 0.83 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8508948 | 0.83 | NT5E (0.49) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL10951219 | 0.82 | NT5E (0.54) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8577146 | 0.82 | SSTR4 (0.63) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19891709 | 0.82 | SSTR1 (0.56) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261614-A2 | METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | SCHERING AKTIENGESELLSCHAFT | 2002-01-03 | — | — | US | disclosed |
| WO-2001068659-A2 | METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | STT3B, MAN1B1, OSTC | SSTR1 4065/4885SSTR2 3996/4885SSTR4 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.